Skip to Content
Merck
CN

SML2861

Sigma-Aldrich

FIT-039

≥98% (HPLC)

Synonym(s):

FIT 039, FIT039, N-(5-Fluoro-2-(piperidin-1-yl)phenyl)pyridine-4-carbothioamide, N-[5-Fluoro-2-(1-piperidinyl)phenyl]-4-pyridinecarbothioamide

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H18FN3S
CAS Number:
1113044-49-7
Molecular Weight:
315.41
MDL number:
MFCD29770796
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

Fc1cc(c(cc1)N3CCCCC3)NC(=S)c2ccncc2

InChI key

VRKZHYSJZOUICG-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

FIT-039 is a potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor that binds to the ATP -binding pocket of CDK9 and inhibits the kinase activity of P-TEFb complex. FIT-039 inhibits replication of herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, and human cytomegalovirus in cultured cells. FIT-039 ointment inhibits formation of skin legion in a mice HSV-1 infection model.
potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor; antiviral agent

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000109832
0000109833
0000102471

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Eriko Sumi et al.
Clinical drug investigation, 39(1), 55-61 (2018-10-05)
Cutaneous warts are caused by human papilloma virus (HPV) infection. FIT039, a specific inhibitor of CDK9, suppresses the proliferation of DNA viruses in vitro. We evaluated the safety, plasma concentrations, and efficacy of FIT039 delivered by single application of an
Makoto Yamamoto et al.
The Journal of clinical investigation, 124(8), 3479-3488 (2014-07-09)
A wide range of antiviral drugs is currently available; however, drug-resistant viruses have begun to emerge and represent a potential public health risk. Here, we explored the use of compounds that inhibit or interfere with the action of essential host
Masahiko Ajiro et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(18), 4518-4528 (2018-05-02)
Purpose: Cervical cancer is one of the leading causes of cancer-related deaths among women worldwide. The purpose of this study is to assess the therapeutic effect of the newly developed cyclin-dependent kinase 9 (CDK9) inhibitor FIT-039 on cervical neoplasia induced

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service